Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch of new investors. The San Diego startup has sunk its teeth into a $137 million series B that will power preparations for a 2027 clinical debut.
- Home |
- OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates
OrbiMed’s Sidewinder slides toward clinic with $137M series B for antibody-drug conjugates
- April 7, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
